The FORECAST study - Focal recurrent assessment and salvage treatment for radiorecurrent prostate cancer

Contemporary Clinical Trials

Volumn 44, Issue , 2015, Pages 175-186

  Kanthabalan, A ^a,b   Shah, T ^a   Arya, M ^b   Punwani, S ^a,b   Bomanji, J ^b   Haroon, A ^a   Illing, R O ^b   Latifoltojar, A ^a,b   Freeman, A ^b   Jameson, C ^b   van der Meulen, J ^c   Charman, S ^c   Emberton, M ^a,b   Ahmed, H U ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Focal salvage therapy; Radio recurrent prostate cancer

Indexed keywords

CHOLINE;

ARTICLE; BONE SCINTISCANNING; CANCER RECURRENCE; CANCER SURGERY; COMPUTER ASSISTED TOMOGRAPHY; CRYOTHERAPY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISTANT METASTASIS; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PROSTATE BIOPSY; PROSTATE CANCER; RADIORECURRENT PROSTATE CANCER; SALVAGE THERAPY; URINE INCONTINENCE; WHOLE BODY MRI;

EID: 84941050821     PISSN: 15517144     EISSN: 15592030     Source Type: Journal    
DOI: 10.1016/j.cct.2015.07.004     Document Type: Article

References (101)

1. Kuban D.A., Thames H.D., Levy L.B., et al. Long-term multiinstitutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int. J. Radiat. Oncol. Biol. Phys. 2003, 57:915-928.
2. Shipley W.U., Thames H.D., Sandler H.M., et al. Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA 1999, 281:1598-1604.
3. Lee W.R., Hanks G.E., Hanlon A. Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations. J. Clin. Oncol. 1997, 15(1):230-238.
4. Roach M., Hanks G., Thames H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int. J. Radiat. Oncol. Biol. Phys. Jul. 15 2006, 65(4):965-974.
5. Critz F.A., Williams W.H., Benton J.B., et al. Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer. J. Urol. 2000, 163:1085-1089.
6. Rosser C.J., Kuban D.A., Levy L.B., et al. Prostate specific antigen bounce phenomenon after external beam radiation for clinically localized prostate cancer. J. Urol. 2002, 168:2001-2005.
7. Hanks G.E., Hanlon A.L., Schultheiss T.E., et al. Conformal external beam treatment of prostate cancer. Urology 1997, 50:87-92.
8. Cavanagh W., Blasko J.C., Grimm P.D., et al. Transient elevation of serum prostate-specific antigen following 125I/103Pd brachytherapy for localized prostate cancer. Semin. Urol. Oncol. 2000, 18:160.
9. Merrick G.S., Gutman S., Andreini H., et al. Prostate cancer distribution in patients diagnosed by transperineal template-guided saturation biopsy. Eur. Urol. Sep. 2007, 52(3):715-723.
10. Crook J., Malone S., Perry G., et al. Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients. Int. J. Radiat. Oncol. Biol. Phys. 2000, 48:355-367.
11. Bostwick D.G., Egbert B.M., Fajardo L.F. Radiation injury of the normal and neoplastic prostate. Am. J. Surg. Pathol. 1982, 6:541-551.
12. Miller E.B., Ladaga L.E., el-Mahdi A.M. Reevaluation of prostate biopsy after definitive radiation therapy. Urology Apr. 1993, 41(4):311-316.
13. Payne H., Khan A., Chowdhury S., et al. Hormone therapy for radiorecurrent prostate cancer. World J. Urol. Dec. 2013, 31(6):1333-1338. 10.1007/s00345-012-0952-8.
14. Heidenreich A., Bastian P.J., Bellmunt J., et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur. Urol. Nov. 12 2013, (pii: S0302-2838(13)01199-8, [Epub ahead of print]). 10.1016/j.eururo.2013.11.002.
15. Pagliarulo V., Bracarda S., Eisenberger M.A., et al. Contemporary role of androgen deprivation therapy for prostate cancer. Eur. Urol. Jan. 2012, 61(1):11-25. 10.1016/j.eururo.2011.08.026.
16. Potosky A.L., Knopf K., Clegg L.X., et al. Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study. J. Clin. Oncol. 2001, 19:3750-3757.
17. Shahinian V.B., Kuo Y.F., Freeman J.L., et al. Risk of fracture after androgen deprivation for prostate cancer. N. Engl. J. Med. 2005, 352:154-164.
18. Jamadar R.J., Winters M.J., Maki P.M. Cognitive changes associated with ADT: a review of the literature. Asian J. Androl. Mar. 2012, 14(2):232-238. 10.1038/aja.2011.107.
19. Strum S.B., McDermed J.E., Scholz M.C., et al. Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br. J. Urol. 1997, 79:933-941.
20. Braga-Basaria M., Dobs A.S., Muller D.C., et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J. Clin. Oncol. 2006, 24:3979-3983.
21. Derweesh I.H., Diblasio C.J., Kincade M.C., et al. Risk of new-onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen-deprivation therapy for prostate cancer. BJU Int. 2007, 100:1060-1065.
22. Saigal C.S., Gore J.L., Krupski T.L., et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007, 110:1493-1500.
23. Thomas B.C., Neal D.E. Androgen deprivation treatment in prostate cancer. BMJ Jan. 8 2013, 346:e8555. 10.1136/bmj.e8555.
24. National Institute for Health and Clinical Excellence Prostate cancer: diagnosis and treatment http://www.nice.org.uk/cg058.
25. Bayoumi A.M., Brown A.D., Garber A.M. Cost-effectiveness of androgen suppression therapies in advanced prostate cancer. J. Natl. Cancer Inst. 2000, 92:1731-1739.
26. Lu L., Peters J., Roome C., Stein K. Cost-effectiveness analysis of degarelix for advanced hormone-dependent prostate cancer. BJU Int. 2012, 109:1183-1192.
27. Ryan C.J., Smith M.R., de Bono J.S., et al. COU-AA-302 investigators. Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med. Jan. 10 2013, 368(2):138-148. (Epub 2012 Dec 10).
28. N. Engl. J. Med. Feb. 7 2013, 368(6):584. Erratum in:.
29. NICE Technology Appraisal 101 Prostate cancer (hormone-refractory) - docetaxel http://www.nice.org.uk/nicemedia/live/11578/33348/33348.pdf.
30. NICE Technology Appraisal 259 Final appraisal determination. Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen http://www.nice.org.uk/nicemedia/live/13484/59217/59217.pdf.
31. Chade D.C., Eastham J., Graefen M., Control Cancer Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature. Eur. Urol. 2012, 61:961-971.
32. Venkatesan K., Zacharakis E., Andrich D.E., et al. Conservative management of urorectal fistulae. Urology Jun. 2013, 81(6):1352-1356. 10.1016/j.urology.2012.10.040.
33. Mundy A.R., Andrich D.E. Posterior urethral complications of the treatment of prostate cancer. BJU Int. 2012, 110(3):304-325.
34. Mundy A.R., Andrich D.E. Urorectal fistulae following the treatment of prostate cancer. BJU Int. Apr. 2011, 107(8):1298-1303. 10.1111/j.1464-410X.2010.09686.x.
35. Elliott S.P., McAninch J.W., Chi T., et al. Management of severe urethral complications of prostate cancer therapy. J. Urol. Dec. 2006, 176(6 Pt 1):2508-2513.
36. Kim I.W., Herts B.R., Jones J.S. Rectourethral fistula after salvage cryotherapy for prostate adenocarcinoma. J. Urol. Feb. 2013, 189(2):699-700. 10.1016/j.juro.2012.10.132.
37. Lane B.R., Stein D.E., Remzi F.H., et al. Management of radiotherapy induced rectourethral fistula. J. Urol. Apr. 2006, 175(4):1382-1387.
38. Torrey R., Rajeshuni N., Ruel N., et al. Radiation history affects continence outcomes after advance transobturator sling placement in patients with post-prostatectomy incontinence. Urology Sep. 2013, 82(3):713-717. 10.1016/j.urology.2013.03.075.
39. Sathianathen N., Moon D., McGuigan S. Outcomes of artificial urinary sphincter implantation in the irradiated patient. BJU Int. Oct. 16 2013, (Epub ahead of print). 10.1111/bju.12518.
40. Nguyen P., D'amico A.V., Lee A.K., et al. Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure. Cancer Oct. 1 2007, 110(7):1417-1428.
41. Ahmed H.U., Akin O., Coleman J.A., et al. Transatlantic consensus group on active surveillance and focal therapy for prostate cancer (appendix). Transatlantic consensus group on active surveillance and focal therapy for prostate cancer. BJU Int. Jun. 2012, 109(11):1636-1647. (Epub 2011 Nov 11. PubMed PMID: 22077593). 10.1111/j.1464-410X.2011.10633.x.
42. Culp S.H., Schellhammer P.F., Williams M.B. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur. Urol. 2014, 65(6):1058-1066.
43. Sooriakumaran P., et al. Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes. BMJ 2014, 348:g1502.
44. Yantorno C., et al. Studies in cryo-immunology. I. The production of antibodies to urogenital tissue in consequence of freezing treatment. Immunology 1967, 12(4):395-410.
45. Shulman S., Brandt E.J., Yantorno C. Studies in cryo-immunology. II. Tissue and species specificity of the autoantibody response and comparison with iso-immunization. Immunology 1968, 14(2):149-158.
46. Blackwood J., Moore F.T., Pace W.G. Cryotherapy for malignant tumors. Cryobiology 1967, 4(1):33-38.
47. Ablin R.J. Cryoimmunotherapy. Br. Med. J. 1972, 3(5824):476.
48. Soanes W.A., Gonder M.J., Ablin R.J. A possible immuno-cryothermic response in prostatic cancer. Clin. Radiol. 1970, 21(3):253-255.
49. Blackwood C.E., Cooper I.S. Response of experimental tumor systems to cryosurgery. Cryobiology 1972, 9(6):508-515.
50. Neel H.B., Ketcham A.S., Hammond W.G. Experimental evaluation of in situ oncocide for primary tumor therapy: comparison of tumor-specific immunity after complete excision, cryonecrosis and ligation. Laryngoscope 1973, 83(3):376-387.
51. Misao A., et al. Late appearance of resistance to tumor rechallenge following cryosurgery. A study in an experimental mammary tumor of the rat. Cryobiology 1981, 18(4):386-389.
52. Allen P.J., et al. The effects of hepatic cryosurgery on tumor growth in the liver. J. Surg. Res. 1998, 77(2):132-136.
53. Yamashita T., et al. Enhanced tumor metastases in rats following cryosurgery of primary tumor. Gann 1982, 73(2):222-228.
54. Urano M., et al. Antitumor effects of residual tumor after cryoablation: the combined effect of residual tumor and a protein-bound polysaccharide on multiple liver metastases in a murine model. Cryobiology 2003, 46(3):238-245.
55. Miya K., et al. Experimental study on mechanism of absorption of cryonecrotized tumor antigens. Cryobiology 1987, 24(2):135-139.
56. Nanus D.M., et al. Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen. J. Urol. 2003, 170(6 Pt 2):S84-S88. (discussion S88-9).
57. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat. Rev. Cancer 2004, 4(1):11-22.
58. Simons J.W., Sacks N. Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer. Urol. Oncol. 2006, 24(5):419-424.
59. Lubaroff D.M., Karan D. CpG oligonucleotide as an adjuvant for the treatment of prostate cancer. Adv. Drug Deliv. Rev. 2009, 61(3):268-274.
60. Levy M.Y., et al. Cyclophosphamide unmasks an antimetastatic effect of local tumor cryoablation. J. Pharmacol. Exp. Ther. 2009, 330(2):596-601.
61. Craig P., Dieppe P., Macintyre S. Developing and evaluating complex interventions: new guidance http://www.mrc.ac.uk/complexinterventionsguidance.
62. Koh D.M., Takahara T., Imai Y., et al. Practical aspects of assessing tumors using clinical diffusion-weighted imaging in the body. Magn. Reson. Med. Sci. 2007, 6:211-224.
63. Komori T., Narabayashi I., Matsumura K., et al. 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography versus whole-body diffusion-weighted MRI for detection of malignant lesions: initial experience. Ann. Nucl. Med. 2007, 21:209-215.
64. Heliou R., Normandeau L., Beaudoin G. Towards dose reduction in CT: patient radiation dose assessment for CT examinations at University Health Center in Canada and comparison with national diagnostic reference levels. Radiat. Prot. Dosim. 2012, 148:202-210.
65. Lecouvet F.E., El Mouedden J., Collette L., et al. Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer?. Eur. Urol. Jul. 2012, 62(1):68-75.
66. Eiber M1., Holzapfel K., Ganter C. Whole-body MRI including diffusion-weighted imaging (DWI) for patients with recurring prostate cancer: technical feasibility and assessment of lesion conspicuity in DWI. J. Magn. Reson. Imaging May 2011, 33(5):1160-1170.
67. Haider M.A., Chung P., Sweet J., et al. Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. Feb. 1 2008, 70(2):425-430. (Epub 2007 Sep 19. PubMed PMID: 17881141).
68. Kara T., Akata D., Akyol F., et al. The values of dynamic contrast-enhanced MRI in the detection of recurrent prostate cancer after external beam radiotherapy: correlation with transrectal ultrasound and pathological findings. Diagn. Interv. Radiol. Mar. 2011, 17. (in press, doi: http://dx.doi.org/10.4261/1305-3825.DIR.3079-09.1. Epub 2010 Aug 12). 10.4261/1305-3825.
69. Roy C., Foudi F., Charton J. Comparative sensitivities of functional MRI sequences in detection of local recurrence of prostate carcinoma after radical prostatectomy or external-beam radiotherapy. AJR Am. J. Roentgenol. Apr. 2013, 200(4):W361-W368. 10.2214/AJR.12.9106.
70. Morgan V.A., Riches S.F., Giles S., et al. Diffusion-weighted MRI for locally recurrent prostate cancer after external beam radiotherapy. AJR Am. J. Roentgenol. Mar. 2012, 198(3):596-602. 10.2214/AJR.11.7162.
71. Arumainayagam N., Kumaar S., Ahmed H.U., et al. Accuracy of multiparametric magnetic resonance imaging in detecting recurrent prostate cancer after radiotherapy. Br. J. Urol. Int. 2010, 106:991-997.
72. Kanthabalan A., Abl-Azzeez M., Arya M., et al. Transperineal MRI-Targeted Biopsy Versus Transperineal Template Prostate Mapping Biopsy in the Detection of Localised Radio-Recurrent Prostate Cancer 2013, (Abstract accepted EAU).
73. Hu Y., Ahmed H.U., Taylor Z., et al. MR to ultrasound registration for image-guided prostate interventions. Med. Image Anal. Apr. 2012, 16(3):687-703.
74. Crawford E.D., Wilson S.S., Torkko K.C., et al. Clinical staging of prostate cancer: a computer-simulated study of transperineal prostate biopsy. BJU Int. Nov. 2005, 96(7):999-1004.
75. Merrick G.S., Gutman S., Andreini H., et al. Prostate cancer distribution in patients diagnosed by transperineal template-guided saturation biopsy. Eur. Urol. Sep. 2007, 52(3):715-723.
76. Pucar D., Hricak H., Shukla-Dave A., et al. Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumour: magnetic resonance imaging and step-section pathology evidence. Int. J. Radiat. Oncol. Biol. Phys. 2007, 69:62-69.
77. Bianco F.J., Scardino P.T., Stephenson A.J. Long term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. Jun. 1 2005, 62(2):448-453.
78. Touma N.J., Izawa J.I., Chin J.L. Current status of local salvage therapies following radiation failure for prostate cancer. J. Urol. 2005, 173:373-379.
79. Kimura M., Mouraviev V., Tsivian M., et al. Current salvage methods for recurrent prostate cancer after failure of primary radiotherapy. BJU Int. 2010, 105(2):191-201.
80. Grado G.L., Collins J.M., Kriegshauser J.S., et al. Salvage brachytherapy for localized prostate cancer after radiotherapy failure. Urology 1999, 53:2-10.
81. Murat F.J., Poissonnier L., Rabilloud M., et al. Mid-term results demonstrate salvage high-intensity focused ultrasound (HIFU) as an effective and acceptably morbid salvage treatment option for locally radiorecurrent prostate cancer. Eur. Urol. 2008, 55:640-649.
82. Uddin Ahmed H., Cathcart P., Chalasani V. Whole-gland salvage high-intensity focused ultrasound therapy for localized prostate cancer recurrence after external beam radiation therapy. Cancer Jun. 15 2012, 118(12):3071-3078.
83. Chalasani V., Martinez C.H., Lim D., et al. Salvage HIFU for recurrent prostate cancer after radiotherapy. Prostate Cancer Prostatic Dis. 2009, 12:124-129.
84. Rebillard X., Soulie M., Chartier-Kastler E., et al. High-intensity focused ultrasound in prostate cancer; a systematic literature review of the French Association of Urology. BJU Int. 2008, 101:1205-1213.
85. Gelet A., Chapelon J.Y., Poissonnier L., et al. Local recurrence of prostate cancer after external beam radiotherapy: early experience of salvage therapy using high intensity focused ultrasonography. Urology 2004, 63:625-629.
86. Valerio, Ahmed H.U., Emberton M., et al. The role of focal therapy in the management of localised prostate cancer: a systematic review. Eur. Urol. Oct. 2014, 66(4):732-751.
87. Ahmed H.U., Cathcart P., McCartan N., et al. Focal salvage therapy for localized prostate cancer recurrence after external beam radiotherapy: a pilot study. Cancer Sep. 1 2012, 118(17):4148-4155.
88. Ismail M., Ahmed S., Kastner C., et al. Salvage cryotherapy for recurrent prostate cancer after radiation failure: a prospective case series of the first 100 patients. BJU Int. 2007, 100:760-764.
89. Pisters L.L., Rewcastle J.C., Donnelly B.J., et al. Salvage prostate cryoablation: initial results from the cryo on-line data registry. J. Urol. 2008, 180:559-563.
90. Ahmed S., Lindsey B., Davies J. Salvage cryosurgery for locally recurrent prostate cancer following radiotherapy. Prostate Cancer Prostatic Dis. 2005, 8:31-35.
91. Galosi A.B., Lugnani F., Muzzonigro G. Salvage cryosurgery for recurrent prostate carcinoma after radiotherapy. J. Endourol. 2007, 21:1-7.
92. Ng C.K., Moussa M., Downey D.B., et al. Salvage cryoablation of the prostate: follow up and analysis of predictive factors for outcome. J. Urol. 2007, 178:1253-1257.
93. Nguyen P., D'amico A.V., Lee A.K., et al. Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure. Cancer 2007, 110:1417-1428.
94. Mouraviev V., Spiess P.E., Jones J.S. Salvage cryoablation for locally recurrent prostate cancer following primary radiotherapy. Eur. Urol. Jun. 2012, 61(6):1204-1211.
95. Li Y.H., Elshafei A., Agarwal G., et al. Salvage focal prostate cryoablation for locally recurrent prostate cancer after radiotherapy: initial results from the cryo on-line data registry. Prostate Jan. 2015, 75(1):1-7. (Epub 2014 Oct 4). 10.1002/pros.22881.
96. de Castro Abreu A.L., Bahn D., Leslie S., et al. Salvage focal and salvage total cryoablation for locally recurrent prostate cancer after primary radiation therapy. BJU Int. Aug. 2013, 112(3):298-307. 10.1111/bju.12151.
97. Barzell W.E., Melamed M.R. Appropriate patient selection in the focal treatment of prostate cancer: the role of transperineal 3-dimensional pathologic mapping of the prostate-a 4-year experience. Urology Dec. 2007, 70(6 Suppl.):27-35.
98. Hu Y., Ahmed H.U., Allen C., et al. MR to ultrasound image registration for guiding prostate biopsy and interventions. Med. Image Comput. Comput. Assist. Interv. 2009, 12(Pt 1):787-794.
99. Zumsteg Z.S., Spratt D.E., Romesser P.B. The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy. Eur. Urol. Jun. 2015, 67(6):1009-1016.
100. Krause B., Souvatzoglou M., Tuncel M., et al. The detection rate of [(11)C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 2008, 35:18-23.
101. Ceci F., Castellucci P., Graziani T., et al. 11C-choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT. Eur. J. Nucl. Med. Mol. Imaging May 2014, 41(5):878-886.